Research suggests that Nigella sativa, commonly known as black cumin or kalonji, demonstrates notable anti-inflammatory activity in preclinical settings, with laboratory and animal studies pointing to its seed preparations, oil, and extracts as sources of biologically active compounds — particularly thymoquinone and alpha-hederin — that appear to modulate inflammatory processes. The available evidence reviewed here is drawn entirely from preclinical research, meaning laboratory and animal studies, with no clinical trials or human studies represented in this summary. While the direction of findings is consistently supportive of anti-inflammatory potential, researchers themselves have flagged significant limitations, including a lack of standardized dosing, inconsistent preparation methods, and an absence of formal safety testing that would be necessary before drawing conclusions about effects in humans. Studies indicate this is a promising area of inquiry, but the evidence base remains at an early stage and further rigorous research, including well-designed human trials, would be needed to substantiate these findings.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Overview of the preclinical pharmacological properties of Nigella sativa (bla... | Other | 2016 | Supports | 100 |